STAGE II PANCREATIC CANCER AJCC V8
Clinical trials for STAGE II PANCREATIC CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE II PANCREATIC CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE II PANCREATIC CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for Hard-to-Treat cancers: drug targets DNA repair weakness
Disease control Recruiting nowThis phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study …
Matched conditions: STAGE II PANCREATIC CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 22, 2026 11:58 UTC
-
New drug combo aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis study tests two experimental drugs, ZEN003694 and entinostat, in people with advanced or treatment-resistant solid tumors, including pancreatic cancer. The goal is to find the safest dose and see if the combination can shrink tumors. About 49 participants will take part in t…
Matched conditions: STAGE II PANCREATIC CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 22, 2026 11:54 UTC
-
Light-activated therapy may boost immune attack on hard-to-treat pancreatic cancer
Disease control Recruiting nowThis study tests a new combination for people with pancreatic cancer that cannot be surgically removed or has spread. It uses a light-activated drug (verteporfin) to make tumors more sensitive to immunotherapy (pembrolizumab), alongside standard chemotherapy. The goal is to see i…
Matched conditions: STAGE II PANCREATIC CANCER AJCC V8
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 17, 2026 12:09 UTC
-
Can a stronger blast of radiation extend life in pancreatic cancer?
Disease control Recruiting nowThis study is for people with locally advanced pancreatic cancer that cannot be removed by surgery. After 4-6 months of chemotherapy, participants will either receive higher-dose radiation or standard care (more chemo, observation, or lower-dose radiation). The goal is to see if …
Matched conditions: STAGE II PANCREATIC CANCER AJCC V8
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 17, 2026 12:06 UTC
-
New hope for pancreatic cancer: targeted pill studied in nationwide telemedicine trial
Disease control Recruiting nowThis study tests a drug called pemigatinib in people with advanced or metastatic pancreatic cancer that has certain changes in the FGFR gene. The drug aims to block these abnormal genes and stop tumor growth. About 40 adults will take the pill at home and be monitored through tel…
Matched conditions: STAGE II PANCREATIC CANCER AJCC V8
Phase: PHASE2 • Sponsor: Sameek Roychowdhury • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
New chemo cocktail shows promise for pancreatic cancer patients before surgery
Disease control Recruiting nowThis study tests whether giving a combination of three chemotherapy drugs (gemcitabine, cisplatin, and nab-paclitaxel) before surgery can help shrink pancreatic tumors and improve outcomes. It includes 36 adults with pancreatic cancer that is either removable or borderline remova…
Matched conditions: STAGE II PANCREATIC CANCER AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 11, 2026 12:09 UTC
-
Pancreatic cancer drug study aims to unlock tumor secrets
Knowledge-focused Recruiting nowThis early-phase trial is testing several drugs (cobimetinib, olaparib, onvansertib, azenosertib, saruparib, and tremelimumab) in people with pancreatic cancer. The goal is to see how these drugs affect tumor biology by comparing biopsies taken before and after treatment. Up to 9…
Matched conditions: STAGE II PANCREATIC CANCER AJCC V8
Phase: EARLY_PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated Jun 23, 2026 21:06 UTC
-
New drug OMO-103 tested in early pancreatic cancer trial
Knowledge-focused Recruiting nowThis early phase 1 trial is studying how the drug OMO-103 affects pancreatic cancer cells in 12 patients with advanced or metastatic pancreatic ductal adenocarcinoma. The main goal is to see if the drug changes the tumor's biology by analyzing tissue samples before and after trea…
Matched conditions: STAGE II PANCREATIC CANCER AJCC V8
Phase: EARLY_PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:06 UTC